Cambridge-based 52North, a medtech company transforming urgent oncology care pathways, has secured €5.7 million ($6 million USD) in funding.
The round was co-led by KHP Ventures, affiliated with King’s Health Partners in London, and Cedars-Sinai Intellectual Property Co. from California. The company also received a €1.4 million ($1.5 million USD) grant from the National Institute for Health and Care Research (NIHR).
Advertisement
Driving Innovations in Oncology Care
The startups’ flagship product, Neutrocheck, is a point-of-care device and app that monitors chemotherapy patients for life-threatening complications like neutropenia and neutropenic sepsis. Earlier this year, Neutrocheck received breakthrough status under the UK Government’s Innovative Devices Access Pathway (IDAP).
The funding will accelerate:
- Advancement of Neutrocheck to market.
- Expansion of the Aster platform, enabling affordable remote cell measurement.
- Launch of ACORN, an AI-based platform aimed at improving acute oncology care, funded by NIHR.
Umaima Ahmad, CEO of 52North, emphasized the milestone: “This funding allows us to scale our product pipeline, collaborate with strategic partners, and reshape urgent care pathways globally.”
Backing from Key Healthcare Leaders
KHP Ventures, the UK’s first NHS-backed venture fund, and Cedars-Sinai, a leading nonprofit healthcare organization in Los Angeles, highlighted their shared vision of revolutionizing patient care.
- Tim Irish, Chair of KHP Ventures: “52North’s solutions empower patients and clinicians, reflecting our commitment to transforming healthcare delivery.”
- Nirdesh Gupta, Managing Partner at Cedars-Sinai: “52North’s innovative oncology care aligns with our mission to drive transformative solutions in healthcare.”
Making Oncology Care Accessible
Founded in 2018 by University of Cambridge postgraduates, 52North focuses on developing low-cost solutions to enhance patient safety across socio-economic groups. The company’s innovations aim to streamline urgent care pathways, benefiting both patients and healthcare providers worldwide.
With this funding, 52North is well-positioned to advance its mission of improving oncology care through cutting-edge technology and strategic collaborations.
